Jennifer Brant is recognized internationally as a thought leader on trade, innovation, and intellectual property, and increasingly on gender and intellectual property (IP) policy. She co-leads the international policy group at Sidley’s office in Geneva. She brings more than 25 years of experience in international law, economics, and development where she advises governments, multinational companies, and international organizations on complex global policy issues.

Jennifer helps clients anticipate and shape the international policy environment that affects their operations. She works with clients on all aspects of policy engagement ― analyzing and forecasting policy shifts, solving complex regulatory and trade challenges, and designing engagement strategies that achieve short- and long-term policy goals. Jennifer’s work is grounded in evidence-based analysis and often involves building innovative coalitions and platforms that unite governments, industry leaders, and international organizations.

H.E. Ambassador Pimchanok Pitfield has served as Thailand’s Ambassador and Permanent Representative to the WTO and WIPO since 2021, following a career in trade policy and diplomacy.

Previously, she was Director-General of the Trade Policy and Strategy Office at Thailand’s Ministry of Commerce, where she advanced technology-driven initiatives, including a Big Data unit and blockchain-based traceability for organic rice. Her career has focused on trade negotiations covering services, investment, e-commerce, environment and labour across the WTO, ASEAN, APEC and bilateral FTAs, complemented by postings in Geneva and Brussels. Her expertise also spans geo-economics, strategic policy, digital economy, trade and sustainability.

Ambassador Pimchanok has served as Ministry of Commerce spokesperson and advisor to government bodies and private-sector associations. She is a member of the Management Board of the Advisory Centre on WTO Law and the Advisory Board of Thailand’s International Health Policy Program Foundation.

H.E. Ambassador Erwin Bollinger is Switzerland’s Ambassador and Permanent Representative to the WTO and EFTA, as well as to UNCTAD, UNECE and ITC in Geneva. Since May 2024, he has served as Chair of the WTO Committee on Trade and Environment. Ambassador Bollinger has worked with the Swiss State Secretariat for Economic Affairs (SECO) since 1992, building more than three decades of experience in international trade and economic policy.

Prior to his current role, he served as Ambassador and Delegate of the Federal Council for Trade Agreements and Head of SECO’s Directorate for Bilateral Economic Relations. Throughout his career, he has held senior positions covering trade negotiations, bilateral economic relations, export controls and sanctions policy, and has represented Switzerland in a range of international trade and regulatory forums.

He has also served at the Swiss Mission to the European Union in Brussels and in Switzerland’s WTO Division. His extensive experience spans WTO affairs, trade agreements, economic diplomacy and international economic cooperation.

Lizzie Wilson is Senior Intellectual Property Attaché at the Permanent Mission of the United Kingdom to the United Nations and other international organisations in Geneva. In this role, she works closely with WIPO and WTO on topics of IP and Trade, addressing policy issues facing governments and stakeholders globally. She has been a UK civil servant for over 15 years with leading roles on immigration, corporate finance and governance, business, IP and international affairs.

Lizzie Wilson qualified from the University of Durham in History and French and also has an MBA from London School of Economics and a diploma in Public Relations. In the UK, Lizzie was a qualified magistrate in North London.

Hemal Shah is Senior Director in Gilead Sciences’ Government Affairs team, where she leads intellectual property and trade policy. Previously, she led policy advocacy on India and emerging markets at the U.S. Chamber of Commerce and held research roles at the American Enterprise Institute and the Legatum Institute in London.

She has participated in the German Marshall Fund’s Young Strategists Forum, the Center for Strategic and International Studies’ Taiwan-U.S. Policy Program, and the American Jewish Committee’s Project Interchange, focusing on U.S. foreign and trade policy.

Hemal has authored more than 40 op-eds and research reports on economic and trade policy, with work featured in the Financial Times, The Economist, The Diplomat, and Foreign Policy. She holds an MSc in Development Studies from the London School of Economics and a BA in Business Management from the University of Nottingham.

David Reddy is Director General of IFPMA, leading the organization’s mission to translate scientific progress into the next generation of medicines and vaccines and championing innovation that delivers a healthier future for people everywhere.

Prior to joining IFPMA, David  served for 13 years as CEO of Medicines for Malaria Venture (MMV), where he played a pivotal role as the organization established the largest portfolio of malaria drugs ever assembled, bringing forward 15 medicines that have saved more than 15 million lives.

In 2026, David joined the World Health Summit Council. He has also been a Board Member of the Coalition for Epidemic Preparedness (CEPI) from 2018-2026 and serves on the Board of Malaria No More UK.

Before joining MMV, David was a Vice President at Roche, where he held corporate responsibility for Roche’s response to the 2009/2010 influenza pandemic. In this role, he led the work to develop, communicate, and implement the company’s strategy for working with governments and the WHO on pandemic preparedness, and establishing a sustainable access program. Prior to this, he led Roche’s HIV/AIDS Disease Area Strategy Team, providing strategic leadership for Roche’s HIV portfolio.

David holds a PhD in Cellular and Molecular Biology from the University of Auckland, New Zealand and completed a post-doctoral fellowship in molecular neurobiology at the Friedrich-Miescher Institute in Basel, Switzerland. David has more than 30 years of management experience in the healthcare sector, including leadership of drug development teams including working on anti-viral diagnostics, a recombinant vaccine, and novel antiviral strategies; licensing and alliance management; market analytics and business planning; product and disease area management; and interfacing with governments, NGOs, and patient advocacy groups in priority disease areas.